Skip to main content

Table 4 The secondary endpoints at baseline and W24

From: Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study

Patient ID

ADL Score

PedsQL TM 4.0 Score

PedsQL TM 3.0 NMM Score

PedsQL TM 2.0FIM Score

Parental Clinical Impression Scale

Blinded video rating

W0

W24

W0

W24

W0

W24

W0

W24

1

75.0

65.0

61.8

23.0

60.0

62.0

50.0

58.8

Slightly worse

Slightly worse

2

10.0

40.0

30.0

27.8

39.0

36.0

71.5

50.0

Same

Slightly better

3

25.0

15.0

36.0

39.5

48.0

49.0

58.8

69.0

Same

Same

4

75.0

85.0

52.8

88.0

75.0

92.0

85.8

85.3

Slightly better

Slightly better

5

85.0

80.0

67.5

56.5

62.0

56.0

63.5

81.8

Slightly worse

Slightly worse

6

10.0

10.0

29.0

25.0

35.0

30.0

50.0

73.8

Slightly worse

Same

7

45.0

45.0

42.5

45.0

52.0

40.0

29.0

45.3

Slightly worse

Markedly worse

8

50.0

55.0

61.3

60.0

/

/

55.5

53.5

Slightly better

Slightly better

9

95.0

95.0

59.8

58.8

68.0

72.0

70.3

75.8

Slightly worse

Slightly worse

10

25.0

25.0

16.0

42.5

38.0

62.0

41.3

40.0

Same

Same

11

85.0

90.0

35.0

73.9

77.0

81.0

50.0

59.5

Slightly better

Slightly better

12

50.0

20.0

23.8

38.3

31.0

44.0

55.5

79.8

Markedly worse

Markedly worse

13

35.0

30.0

65.8

35.0

/

/

41.3

40.0

Slightly worse

Slightly worse

14

50.0

40.0

35.8

22.5

40.0

45.0

58.8

60.8

Slightly worse

Slightly worse

15

50.0

35.0

36.0

44.8

52.0

49.0

32.5

46.5

Markedly worse

Markedly worse

M ± SD

49.3 ± 28.1

53.0 ± 25.1

55.2 ± 18.1

45.3 ± 19.1

52.1 ± 15.4

55.2 ± 18.1

54.2 ± 15.1

61.3 ± 15.4

/

/

t

1.361a

0.332a

1.142a

2.306a

/

/

P

0.195a

0.745a

0.276a

0.037a

/

/

  1. “/” means no statistical analysis was performed
  2. “a” means difference between W24 and W0, Paired t test was performed